Why is Syncom Formulations (India) Ltd falling/rising?

Recent Price Momentum and Market Outperformance

Syncom Formulations has demonstrated impressive short-term gains, outperforming its sector by 5.49% on the day. The stock has been on a positive trajectory for two consecutive days, delivering an 8.46% return over this brief period. This surge is further supported by rising investor participation, with delivery volumes on 03 Feb reaching 11.01 lakh shares—a 21.24% increase compared to the five-day average. Such heightened liquidity and trading activity suggest renewed confidence among market participants.

Technically, the stock is trading above its 5-day and 20-day moving averages, signalling short-term strength, although it remains below its longer-term averages such as the 50-day, 100-day, and 200-day marks. This positioning indicates that while recent momentum is positive, the stock has yet to fully recover from prior declines.

Strong Operational Performance Underpinning Recent Gains

Syncom’s recent financial results have been encouraging. The company reported an 8.29% growth in operating profit in the half-year ended September 2025, marking its sixth consecutive quarter of positive results. Net sales for the latest six months stood at ₹238.62 crore, reflecting a robust 25.87% increase, while profit after tax (PAT) surged by 72.46% to ₹32.32 crore. These figures highlight a significant improvement in the company’s core business operations and profitability.

Additionally, the company boasts a low average debt-to-equity ratio of 0.05 times, indicating a conservative capital structure that reduces financial risk. Its return on capital employed (ROCE) for the half-year is a healthy 22.06%, and return on equity (ROE) stands at 16.6%, suggesting efficient utilisation of shareholder funds. Despite trading at a premium price-to-book value of 3.5 relative to peers, the company’s PEG ratio of 0.2 implies that its earnings growth is not fully priced into the stock, potentially justifying the current valuation.

Mixed Long-Term Performance and Market Sentiment

However, the stock’s longer-term performance paints a more cautious picture. Over the past year, Syncom’s share price has declined by 21.75%, significantly underperforming the Sensex, which gained 6.66% during the same period. This underperformance extends to the broader BSE500 index, which returned 7.87% over the last year, underscoring the stock’s relative weakness.

Moreover, the company’s net sales and operating profit have contracted sharply over the last five years, with annualised declines of 63.63% and 52.27% respectively. Such negative trends raise concerns about sustainable growth prospects. The absence of domestic mutual fund holdings, which remain at zero, may reflect institutional caution or scepticism regarding the company’s valuation or business model.

Balancing Short-Term Optimism with Long-Term Caution

In summary, Syncom Formulations’ recent price rise is primarily driven by strong operational results, improved profitability, and increased investor interest. The company’s ability to deliver positive earnings growth and maintain a low debt profile has helped it outperform its sector in the short term. Nevertheless, the stock’s longer-term underperformance and declining sales over five years temper enthusiasm, signalling that investors should weigh these factors carefully.

For those considering exposure to Syncom, the current rally may offer an opportunity to capitalise on improving fundamentals. However, the lack of institutional backing and historical sales contraction suggest that a cautious approach remains prudent until sustained growth is more clearly established.

Get 2 full years of MojoOne Premium for only Rs. 12,999. Subscribe for 1 year and we'll add another year FREE. Offer valid for a limited time. Start Saving Now →